Selecting multimodal therapy for rhabdomyosarcoma

References

• Parham DM, Ellison DA. Rhabdomyosarcomas in adults and children: an update. Arch. Pathol. Lab. Med.130(10), 1454–1465 (2006).
   PubMed Web of Science ®Google Scholar
• Surveillance, Epidemiology, and End Results (SEER) Program SEER*Stat Database: Incidence – SEER 9 Regs Limited-Use, Nov 2008 Sub (1973–2006) <Katrina/Rita Population Adjustment> – Linked To County Attributes - Total U.S., 1969–2006 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2009, based on the November 2008 submission.
   Google Scholar
• Sultan I, Qaddoumi I, Yaser S, Rodriguez-Galindo C, Ferrari A. Comparing adult and pediatric rhabdomyosarcoma in the surveillance, epidemiology and end results program, 1973 to 2005: an analysis of 2,600 patients. J. Clin. Oncol.27(20), 3391–3397 (2009).
   PubMed Web of Science ®Google Scholar
• Newton WA Jr, Gehan EA, Webber BL et al. Classification of rhabdomyosarcomas and related sarcomas. Pathologic aspects and proposal for a new classification – an Intergroup Rhabdomyosarcoma Study. Cancer76(6), 1073–1085 (1995).
   PubMed Web of Science ®Google Scholar
• Raney RB, Anderson JR, Barr FG et al. Rhabdomyosarcoma and undifferentiated sarcoma in the first two decades of life: a selective review of Intergroup Rhabdomyosarcoma Study Group experience and rationale for Intergroup Rhabdomyosarcoma Study V. J. Pediatr. Hematol. Oncol.23(4), 215–220 (2001).
   PubMed Web of Science ®Google Scholar
• Raney RB, Maurer HM, Anderson JR et al. The Intergroup Rhabdomyosarcoma Study Group (IRSG): major lessons from the IRS-I through IRS-IV studies as background for the current IRS-V treatment protocols. Sarcoma5(1), 9–15 (2001).
   PubMedGoogle Scholar
• Stevens MC, Rey A, Bouvet N et al. Treatment of nonmetastatic rhabdomyosarcoma in childhood and adolescence: third study of the International Society of Paediatric Oncology – SIOP Malignant Mesenchymal Tumor 89. J. Clin. Oncol.23(12), 2618–2628 (2005).
   PubMed Web of Science ®Google Scholar
• Defachelles AS, Rey A, Oberlin O, Spooner D, Stevens MC. Treatment of nonmetastatic cranial parameningeal rhabdomyosarcoma in children younger than 3 years old: results from International Society of Pediatric Oncology studies MMT 89 and 95. J. Clin. Oncol.27(8), 1310–1315 (2009).
   PubMedGoogle Scholar
• Modritz D, Ladenstein R, Potschger U et al. Treatment for soft tissue sarcoma in childhood and adolescence. Austrian results within the CWS 96 study. Wien Klin. Wochenschr.117(5–6), 196–209 (2005).
   PubMedGoogle Scholar
• Dantonello TM, Int-Veen C, Harms D et al. Cooperative trial CWS-91 for localized soft tissue sarcoma in children, adolescents, and young adults. J. Clin. Oncol.27(9), 1446–1455 (2009).
   PubMed Web of Science ®Google Scholar
• Bisogno G, De Rossi C, Gamboa Y et al. Improved survival for children with parameningeal rhabdomyosarcoma: results from the AIEOP Soft Tissue Sarcoma Committee. Pediatr. Blood Cancer50(6), 1154–1158 (2008).
   PubMed Web of Science ®Google Scholar
• Cecchetto G, Carretto E, Bisogno G et al. Complete second look operation and radiotherapy in locally advanced non-alveolar rhabdomyosarcoma in children: a report from the AIEOP Soft Tissue Sarcoma Committee. Pediatr. Blood Cancer51(5), 593–597 (2008).
   PubMedGoogle Scholar
• Crist WM, Garnsey L, Beltangady MS et al. Prognosis in children with rhabdomyosarcoma: a report of the Intergroup Rhabdomyosarcoma Studies I and II. Intergroup Rhabdomyosarcoma Committee. J. Clin. Oncol.8(3), 443–452 (1990).
   PubMed Web of Science ®Google Scholar
• Joshi D, Anderson JR, Paidas C, Breneman J, Parham DM, Crist W. Age is an independent prognostic factor in rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children’s Oncology Group. Pediatr. Blood Cancer42(1), 64–73 (2004).
   PubMed Web of Science ®Google Scholar
• Meza JL, Anderson J, Pappo AS, Meyer WH. Analysis of prognostic factors in patients with nonmetastatic rhabdomyosarcoma treated on Intergroup Rhabdomyosarcoma Studies III and IV: the Children’s Oncology Group. J. Clin. Oncol.24(24), 3844–3851 (2006).
   PubMed Web of Science ®Google Scholar
• Neville HL, Andrassy RJ, Lobe TE et al. Preoperative staging, prognostic factors, and outcome for extremity rhabdomyosarcoma: a preliminary report from the Intergroup Rhabdomyosarcoma Study IV (1991–1997). J. Pediatr. Surg.35(2), 317–321 (2000).
   PubMed Web of Science ®Google Scholar
• Rodary C, Gehan EA, Flamant F et al. Prognostic factors in 951 nonmetastatic rhabdomyosarcoma in children: a report from the International Rhabdomyosarcoma Workshop. Med. Pediatr. Oncol.19(2), 89–95 (1991).
   PubMedGoogle Scholar
• Rodary C, Rey A, Olive D et al. Prognostic factors in 281 children with nonmetastatic rhabdomyosarcoma (RMS) at diagnosis. Med. Pediatr. Oncol.16(2), 71–77 (1988).
   PubMedGoogle Scholar
• Koscielniak E, Harms D, Henze G et al. Results of treatment for soft tissue sarcoma in childhood and adolescence: a final report of the German Cooperative Soft Tissue Sarcoma Study CWS-86. J. Clin. Oncol.17(12), 3706–3719 (1999).
   PubMed Web of Science ®Google Scholar
• Burke M, Anderson JR, Kao SC et al. Assessment of response to induction therapy and its influence on 5-year failure-free survival in group III rhabdomyosarcoma: the Intergroup Rhabdomyosarcoma Study-IV experience. A report from the Soft Tissue Sarcoma Committee of the Children’s Oncology Group. J. Clin. Oncol.25(31), 4909–4913 (2007).
   PubMedGoogle Scholar
• Ferrari A, Miceli R, Meazza C et al. Comparison of the prognostic value of assessing tumor diameter versus tumor volume at diagnosis or in response to initial chemotherapy in rhabdomyosarcoma. J. Clin. Oncol.28(8), 1322–1328 (2010).
   PubMed Web of Science ®Google Scholar
• Ferrari A, Miceli R, Meazza C et al. Soft tissue sarcomas of childhood and adolescence: the prognostic role of tumor size in relation to patient body size. J. Clin. Oncol.27(3), 371–376 (2009).
   PubMedGoogle Scholar
• Loh WE Jr, Scrable HJ, Livanos E et al. Human chromosome 11 contains two different growth suppressor genes for embryonal rhabdomyosarcoma. Proc. Natl Acad. Sci. USA89(5), 1755–1759 (1992).
   PubMedGoogle Scholar
• Bridge JA, Liu J, Weibolt V et al. Novel genomic imbalances in embryonal rhabdomyosarcoma revealed by comparative genomic hybridization and fluorescence in situ hybridization: an intergroup rhabdomyosarcoma study. Genes Chromosomes Cancer27(4), 337–344 (2000).
   PubMedGoogle Scholar
• Davicioni E, Anderson MJ, Finckenstein FG et al. Molecular classification of rhabdomyosarcoma – genotypic and phenotypic determinants of diagnosis: a report from the Children’s Oncology Group. Am. J. Pathol.174(2), 550–564 (2009).
   PubMed Web of Science ®Google Scholar
• Barr FG, Smith LM, Lynch JC et al. Examination of gene fusion status in archival samples of alveolar rhabdomyosarcoma entered on the Intergroup Rhabdomyosarcoma Study-III trial: a report from the Children’s Oncology Group. J. Mol. Diagn.8(2), 202–208 (2006).
   PubMed Web of Science ®Google Scholar
• Sorensen PH, Lynch JC, Qualman SJ et al.PAX3–FKHR and PAX7–FKHR gene fusions are prognostic indicators in alveolar rhabdomyosarcoma: a report from the Children’s Oncology Group. J. Clin. Oncol.20(11), 2672–2679 (2002).
   PubMed Web of Science ®Google Scholar
• Williamson D, Missiaglia E, de Reynies A et al. Fusion gene-negative alveolar rhabdomyosarcoma is clinically and molecularly indistinguishable from embryonal rhabdomyosarcoma. J. Clin. Oncol.28(13), 2151–2158 (2010).
   PubMed Web of Science ®Google Scholar
• Breitfeld PP, Meyer WH. Rhabdomyosarcoma: new windows of opportunity. Oncologist10(7), 518–527 (2005).
   PubMedGoogle Scholar
• Koscielniak E, Jurgens H, Winkler K et al. Treatment of soft tissue sarcoma in childhood and adolescence. A report of the German Cooperative Soft Tissue Sarcoma Study. Cancer70(10), 2557–2567 (1992).
   PubMed Web of Science ®Google Scholar
• Meyer WH, Spunt SL. Soft tissue sarcomas of childhood. Cancer Treat. Rev.30(3), 269–280 (2004).
   PubMed Web of Science ®Google Scholar
• Ruymann FB, Grovas AC. Progress in the diagnosis and treatment of rhabdomyosarcoma and related soft tissue sarcomas. Cancer Invest.18(3), 223–241 (2000).
   PubMed Web of Science ®Google Scholar
• Ferrari A, Casanova M. Current chemotherapeutic strategies for rhabdomyosarcoma. Expert Rev. Anticancer Ther.5(2), 283–294 (2005).
   PubMed Web of Science ®Google Scholar
• Parham DM. Pathologic classification of rhabdomyosarcomas and correlations with molecular studies. Mod. Pathol.14(5), 506–514 (2001).
   PubMed Web of Science ®Google Scholar
• Mazzoleni S, Bisogno G, Garaventa A et al. Outcomes and prognostic factors after recurrence in children and adolescents with nonmetastatic rhabdomyosarcoma. Cancer104(1), 183–190 (2005).
   PubMedGoogle Scholar
• Pappo AS, Anderson JR, Crist WM et al. Survival after relapse in children and adolescents with rhabdomyosarcoma: a report from the Intergroup Rhabdomyosarcoma Study Group. J. Clin. Oncol.17(11), 3487–3493 (1999).
   PubMedGoogle Scholar
• Donaldson SS, Anderson JR. Rhabdomyosarcoma: many similarities, a few philosophical differences. J. Clin. Oncol.23(12), 2586–2587 (2005).
   PubMed Web of Science ®Google Scholar
• Stevens MC. Treatment for childhood rhabdomyosarcoma: the cost of cure. Lancet Oncol.6(2), 77–84 (2005).
   PubMed Web of Science ®Google Scholar
• Hays DM, Lawrence W Jr, Wharam M et al. Primary reexcision for patients with ‘microscopic residual’ tumor following initial excision of sarcomas of trunk and extremity sites. J. Pediatr. Surg.24(1), 5–10 (1989).
   PubMed Web of Science ®Google Scholar
• Raney RB, Stoner JA, Walterhouse DO et al. Results of treatment of fifty-six patients with localized retroperitoneal and pelvic rhabdomyosarcoma: a report from the Intergroup Rhabdomyosarcoma Study-IV, 1991–1997. Pediatr. Blood Cancer42(7), 618–625 (2004).
   PubMedGoogle Scholar
• Hays DM, Raney RB, Crist WM et al. Secondary surgical procedures to evaluate primary tumor status in patients with chemotherapy-responsive stage III and IV sarcomas: a report from the Intergroup Rhabdomyosarcoma Study. J. Pediatr. Surg.25(10), 1100–1105 (1990).
   PubMedGoogle Scholar
• Chui CH, Billups CA, Pappo AS, Rao BN, Spunt SL. Predictors of outcome in children and adolescents with rhabdomyosarcoma of the trunk – the St Jude Children’s Research Hospital experience. J. Pediatr. Surg.40(11), 1691–1695 (2005).
   PubMedGoogle Scholar
• Arndt CA, Hammond S, Rodeberg D, Qualman S. Significance of persistent mature rhabdomyoblasts in bladder/prostate rhabdomyosarcoma: results from IRS IV. J. Pediatr. Hematol. Oncol.28(9), 563–567 (2006).
   PubMed Web of Science ®Google Scholar
• Oberlin O, Rey A, Anderson J et al. Treatment of orbital rhabdomyosarcoma: survival and late effects of treatment – results of an international workshop. J. Clin. Oncol.19(1), 197–204 (2001).
   PubMed Web of Science ®Google Scholar
• Buwalda J, Schouwenburg PF, Blank LE et al. A novel local treatment strategy for advanced stage head and neck rhabdomyosarcomas in children: results of the AMORE protocol. Eur. J. Cancer39(11), 1594–1602 (2003).
   PubMedGoogle Scholar
• Dall’Igna P, Bisogno G, Ferrari A et al. Primary transcrotal excision for paratesticular rhabdomyosarcoma: is hemiscrotectomy really mandatory? Cancer97(8), 1981–1984 (2003).
   PubMedGoogle Scholar
• Ferrari A, Bisogno G, Casanova M et al. Paratesticular rhabdomyosarcoma: report from the Italian and German Cooperative Group. J. Clin. Oncol.20(2), 449–455 (2002).
   PubMed Web of Science ®Google Scholar
• Olive D, Flamant F, Zucker JM et al. Paraaortic lymphadenectomy is not necessary in the treatment of localized paratesticular rhabdomyosarcoma. Cancer54(7), 1283–1287 (1984).
   PubMedGoogle Scholar
• Stewart RJ, Martelli H, Oberlin O et al. Treatment of children with nonmetastatic paratesticular rhabdomyosarcoma: results of the Malignant Mesenchymal Tumors studies (MMT 84 and MMT 89) of the International Society of Pediatric Oncology. J. Clin. Oncol.21(5), 793–798 (2003).
   PubMed Web of Science ®Google Scholar
• Wiener ES, Anderson JR, Ojimba JI et al. Controversies in the management of paratesticular rhabdomyosarcoma: is staging retroperitoneal lymph node dissection necessary for adolescents with resected paratesticular rhabdomyosarcoma? Semin. Pediatr. Surg.10(3), 146–152 (2001).
   PubMedGoogle Scholar
• Wiener ES, Lawrence W, Hays D et al. Retroperitoneal node biopsy in paratesticular rhabdomyosarcoma. J. Pediatr. Surg.29(2), 171–177 (1994).
   PubMed Web of Science ®Google Scholar
• Arndt C, Rodeberg D, Breitfeld PP, Raney RB, Ullrich F, Donaldson S. Does bladder preservation (as a surgical principle) lead to retaining bladder function in bladder/prostate rhabdomyosarcoma? Results from Intergroup Rhabdomyosarcoma Study IV. J. Urol.171(6 Pt 1), 2396–2403 (2004).
   PubMed Web of Science ®Google Scholar
• Martelli H, Haie-Meder C, Branchereau S et al. Conservative surgery plus brachytherapy treatment for boys with prostate and/or bladder neck rhabdomyosarcoma: a single team experience. J. Pediatr. Surg.44(1), 190–196 (2009).
   PubMed Web of Science ®Google Scholar
• Crist W, Gehan EA, Ragab AH et al. The Third Intergroup Rhabdomyosarcoma Study. J. Clin. Oncol.13(3), 610–630 (1995).
   PubMed Web of Science ®Google Scholar
• Crist WM, Anderson JR, Meza JL et al. Intergroup Rhabdomyosarcoma Study-IV: results for patients with nonmetastatic disease. J. Clin. Oncol.19(12), 3091–3102 (2001).
   PubMed Web of Science ®Google Scholar
• Flamant F, Rodary C, Rey A et al. Treatment of non-metastatic rhabdomyosarcomas in childhood and adolescence. Results of the second study of the International Society of Paediatric Oncology: MMT84. Eur. J. Cancer34(7), 1050–1062 (1998).
   PubMed Web of Science ®Google Scholar
• Maurer HM, Beltangady M, Gehan EA et al. The Intergroup Rhabdomyosarcoma Study-I. A final report. Cancer61(2), 209–220 (1988).
   PubMed Web of Science ®Google Scholar
• Wolden SL, Anderson JR, Crist WM et al. Indications for radiotherapy and chemotherapy after complete resection in rhabdomyosarcoma: a report from the Intergroup Rhabdomyosarcoma Studies I to III. J. Clin. Oncol.17(11), 3468–3475 (1999).
   PubMed Web of Science ®Google Scholar
• Schuck A, Mattke AC, Schmidt B et al. Group II rhabdomyosarcoma and rhabdomyosarcomalike tumors: is radiotherapy necessary? J. Clin. Oncol.22(1), 143–149 (2004).
   PubMedGoogle Scholar
• Viswanathan AN, Grier HE, Litman HJ et al. Outcome for children with group III rhabdomyosarcoma treated with or without radiotherapy. Int. J. Radiat. Oncol. Biol. Phys.58(4), 1208–1214 (2004).
   PubMed Web of Science ®Google Scholar
• Wharam MD, Hanfelt JJ, Tefft MC et al. Radiation therapy for rhabdomyosarcoma: local failure risk for clinical group III patients on Intergroup Rhabdomyosarcoma Study II. Int. J. Radiat. Oncol. Biol. Phys.38(4), 797–804 (1997).
   PubMed Web of Science ®Google Scholar
• Arndt CA, Donaldson SS, Anderson JR et al. What constitutes optimal therapy for patients with rhabdomyosarcoma of the female genital tract? Cancer91(12), 2454–2468 (2001).
   PubMed Web of Science ®Google Scholar
• Maurer HM, Gehan EA, Beltangady M et al. The Intergroup Rhabdomyosarcoma Study-II. Cancer71(5), 1904–1922 (1993).
   PubMed Web of Science ®Google Scholar
• Michalski JM, Meza J, Breneman JC et al. Influence of radiation therapy parameters on outcome in children treated with radiation therapy for localized parameningeal rhabdomyosarcoma in Intergroup Rhabdomyosarcoma Study Group trials II through IV. Int. J. Radiat. Oncol. Biol. Phys.59(4), 1027–1038 (2004).
   PubMedGoogle Scholar
• Raney RB, Meza J, Anderson JR et al. Treatment of children and adolescents with localized parameningeal sarcoma: experience of the Intergroup Rhabdomyosarcoma Study Group protocols IRS-II through -IV, 1978–1997. Med. Pediatr. Oncol.38(1), 22–32 (2002).
   PubMedGoogle Scholar
• Meazza C, Ferrari A, Casanova M et al. Evolving treatment strategies for parameningeal rhabdomyosarcoma: the experience of the Istituto Nazionale Tumori of Milan. Head Neck27(1), 49–57 (2005).
   PubMedGoogle Scholar
• Combs SE, Behnisch W, Kulozik AE, Huber PE, Debus J, Schulz-Ertner D. Intensity modulated radiotherapy (IMRT) and fractionated stereotactic radiotherapy (FSRT) for children with head-and-neck-rhabdomyosarcoma. BMC Cancer7, 177 (2007).
   PubMed Web of Science ®Google Scholar
• Laskar S, Bahl G, Ann Muckaden M et al. Interstitial brachytherapy for childhood soft tissue sarcoma. Pediatr. Blood Cancer49(5), 649–655 (2007).
   PubMedGoogle Scholar
• McDonald MW, Esiashvili N, George BA et al. Intensity-modulated radiotherapy with use of cone-down boost for pediatric head-and-neck rhabdomyosarcoma. Int. J. Radiat. Oncol. Biol. Phys.72(3), 884–891 (2008).
   PubMedGoogle Scholar
• Curtis AE, Okcu MF, Chintagumpala M, Teh BS, Paulino AC. Local control after intensity-modulated radiotherapy for head-and-neck rhabdomyosarcoma. Int. J. Radiat. Oncol. Biol. Phys.73(1), 173–177 (2009).
   PubMedGoogle Scholar
• Donaldson SS, Asmar L, Breneman J et al. Hyperfractionated radiation in children with rhabdomyosarcoma – results of an Intergroup Rhabdomyosarcoma Pilot Study. Int. J. Radiat. Oncol. Biol. Phys.32(4), 903–911 (1995).
   PubMed Web of Science ®Google Scholar
• Mandell LR, Ghavimi F, Exelby P, Fuks Z. Preliminary results of alternating combination chemotherapy (CT) and hyperfractionated radiotherapy (HART) in advanced rhabdomyosarcoma (RMS). Int. J. Radiat. Oncol. Biol. Phys.15(1), 197–203 (1988).
   PubMed Web of Science ®Google Scholar
• Heyn R, Holland R, Joo P et al. Treatment of rhabdomyosarcoma in children with surgery, radiotherapy and chemotherapy. Med. Pediatr. Oncol.3(1), 21–32 (1977).
   PubMedGoogle Scholar
• Carli M, Pastore G, Perilongo G et al. Tumor response and toxicity after single high-dose versus standard five-day divided-dose dactinomycin in childhood rhabdomyosarcoma. J. Clin. Oncol.6(4), 654–658 (1988).
   PubMed Web of Science ®Google Scholar
• Spunt SL, Smith LM, Ruymann FB et al. Cyclophosphamide dose intensification during induction therapy for intermediate-risk pediatric rhabdomyosarcoma is feasible but does not improve outcome: a report from the Soft Tissue Sarcoma Committee of the Children’s Oncology Group. Clin. Cancer Res.10(18 Pt 1), 6072–6079 (2004).
   PubMed Web of Science ®Google Scholar
• Treuner J, Koscielniak E, Keim M. Comparison of the rates of response to ifosfamide and cyclophosphamide in primary unresectable rhabdomyosarcomas. Cancer Chemother. Pharmacol.24(Suppl. 1), S48–S50 (1989).
   Google Scholar
• Arndt CA, Stoner JA, Hawkins DS et al. Vincristine, actinomycin, and cyclophosphamide compared with vincristine, actinomycin, and cyclophosphamide alternating with vincristine, topotecan, and cyclophosphamide for intermediate-risk rhabdomyosarcoma: Children’s Oncology Group Study D9803. J. Clin. Oncol.27(31), 5182–5188 (2009).
   PubMed Web of Science ®Google Scholar
• Mascarenhas L, Lyden ER, Breitfeld PP et al. Randomized Phase II window study of two schedules of irinotecan (CPT-11) and vincristine (VCR) in rhabdomyosarcoma (RMS) at first relapse/disease progression. J. Clin. Oncol.26(15 Suppl.) (2008) (Abstract 10013).
   Google Scholar
• Stevens M, Rey A, Bouvet N. SIOP MMT95: Intensified (6 drug) versus standard (IVA) chemotherapy for high risk nonmetastatic rhabdomyosarcoma (RMS). J. Clin. Oncol.15, 802s (2004) (Abstract 8515).
   Google Scholar
• Breitfeld PP, Lyden E, Raney RB et al. Ifosfamide and etoposide are superior to vincristine and melphalan for pediatric metastatic rhabdomyosarcoma when administered with irradiation and combination chemotherapy: a report from the Intergroup Rhabdomyosarcoma Study Group. J. Pediatr. Hematol. Oncol.23(4), 225–233 (2001).
   PubMed Web of Science ®Google Scholar
• Klingebiel T, Boos J, Beske F et al. Treatment of children with metastatic soft tissue sarcoma with oral maintenance compared with high dose chemotherapy: report of the HD CWS-96 trial. Pediatr. Blood Cancer50(4), 739–745 (2008).
   PubMed Web of Science ®Google Scholar
• Lager JJ, Lyden ER, Anderson JR, Pappo AS, Meyer WH, Breitfeld PP. Pooled analysis of Phase II window studies in children with contemporary high-risk metastatic rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children’s Oncology Group. J. Clin. Oncol.24(21), 3415–3422 (2006).
   PubMedGoogle Scholar
• Smith MA, Anderson B. Phase II window studies: 10 years of experience and counting. J. Pediatr. Hematol. Oncol.23(6), 334–337 (2001).
   PubMed Web of Science ®Google Scholar
• Walterhouse DO, Lyden ER, Breitfeld PP, Qualman SJ, Wharam MD, Meyer WH. Efficacy of topotecan and cyclophosphamide given in a Phase II window trial in children with newly diagnosed metastatic rhabdomyosarcoma: a Children’s Oncology Group study. J. Clin. Oncol.22(8), 1398–1403 (2004).
   PubMedGoogle Scholar
• Blaney SM, Needle MN, Gillespie A et al. Phase II trial of topotecan administered as 72-hour continuous infusion in children with refractory solid tumors: a collaborative Pediatric Branch, National Cancer Institute, and Children’s Cancer Group Study. Clin. Cancer Res.4(2), 357–360 (1998).
   PubMed Web of Science ®Google Scholar
• Nitschke R, Parkhurst J, Sullivan J, Harris MB, Bernstein M, Pratt C. Topotecan in pediatric patients with recurrent and progressive solid tumors: a Pediatric Oncology Group Phase II study. J. Pediatr. Hematol. Oncol.20(4), 315–318 (1998).
   PubMed Web of Science ®Google Scholar
• Pappo AS, Lyden E, Breneman J et al. Up-front window trial of topotecan in previously untreated children and adolescents with metastatic rhabdomyosarcoma: an Intergroup Rhabdomyosarcoma Study. J. Clin. Oncol.19(1), 213–219 (2001).
   PubMed Web of Science ®Google Scholar
• Saylors RL 3rd, Stine KC, Sullivan J et al. Cyclophosphamide plus topotecan in children with recurrent or refractory solid tumors: a Pediatric Oncology Group Phase II study. J. Clin. Oncol.19(15), 3463–3469 (2001).
   PubMed Web of Science ®Google Scholar
• Rodriguez-Galindo C, Crews KR, Stewart CF et al. Phase I study of the combination of topotecan and irinotecan in children with refractory solid tumors. Cancer Chemother. Pharmacol.57(1), 15–24 (2006).
   PubMedGoogle Scholar
• Meazza C, Casanova M, Zaffignani E et al. Efficacy of topotecan plus vincristine and doxorubicin in children with recurrent/refractory rhabdomyosarcoma. Med. Oncol.26(1), 67–72 (2009).
   PubMedGoogle Scholar
• Houghton PJ, Cheshire PJ, Hallman JD 2nd et al. Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors. Cancer Chemother. Pharmacol.36(5), 393–403 (1995).
   PubMed Web of Science ®Google Scholar
• Vassal G, Terrier-Lacombe MJ, Bissery MC et al. Therapeutic activity of CPT-11, a DNA-topoisomerase I inhibitor, against peripheral primitive neuroectodermal tumour and neuroblastoma xenografts. Br. J. Cancer74(4), 537–545 (1996).
   PubMed Web of Science ®Google Scholar
• Bisogno G, Riccardi R, Ruggiero A et al. Phase II study of a protracted irinotecan schedule in children with refractory or recurrent soft tissue sarcoma. Cancer106(3), 703–707 (2006).
   PubMed Web of Science ®Google Scholar
• Pappo AS, Lyden E, Breitfeld P et al. Two consecutive Phase II window trials of irinotecan alone or in combination with vincristine for the treatment of metastatic rhabdomyosarcoma: the Children’s Oncology Group. J. Clin. Oncol.25(4), 362–369 (2007).
   PubMedGoogle Scholar
• Casey DA, Wexler LH, Merchant MS et al. Irinotecan and temozolomide for Ewing sarcoma: the Memorial Sloan–Kettering experience. Pediatr. Blood Cancer53(6), 1029–1034 (2009).
   PubMed Web of Science ®Google Scholar
• Wagner LM, McAllister N, Goldsby RE et al. Temozolomide and intravenous irinotecan for treatment of advanced Ewing sarcoma. Pediatr. Blood Cancer48(2), 132–139 (2007).
   PubMed Web of Science ®Google Scholar
• Levy AS, Meyers PA, Wexler LH et al. Phase 1 and pharmacokinetic study of concurrent carboplatin and irinotecan in subjects aged 1 to 21 years with refractory solid tumors. Cancer115(1), 207–216 (2009).
   PubMedGoogle Scholar
• McGregor LM, Spunt SL, Furman WL et al. Phase 1 study of oxaliplatin and irinotecan in pediatric patients with refractory solid tumors: a Children’s Oncology Group study. Cancer115(8), 1765–1775 (2009).
   PubMedGoogle Scholar
• Furman WL, Crews KR, Billups C et al. Cefixime allows greater dose escalation of oral irinotecan: a Phase I study in pediatric patients with refractory solid tumors. J. Clin. Oncol.24(4), 563–570 (2006).
   PubMed Web of Science ®Google Scholar
• Ferraldeschi R, Minchell LJ, Roberts SA et al.UGT1A1*28 genotype predicts gastrointestinal toxicity in patients treated with intermediate-dose irinotecan. Pharmacogenomics10(5), 733–739 (2009).
   PubMed Web of Science ®Google Scholar
• Furman WL, Navid F, Daw NC et al. Tyrosine kinase inhibitor enhances the bioavailability of oral irinotecan in pediatric patients with refractory solid tumors. J. Clin. Oncol.27(27), 4599–4604 (2009).
   PubMed Web of Science ®Google Scholar
• Bonadonna G, Monfardini S, De Lena M, Fossati-Bellani F, Beretta G. Phase I and preliminary Phase II evaluation of adriamycin (NSC 123127). Cancer Res.30(10), 2572–2582 (1970).
   PubMed Web of Science ®Google Scholar
• O’Bryan RM, Luce JK, Talley RW, Gottlieb JA, Baker LH, Bonadonna G. Phase II evaluation of adriamycin in human neoplasia. Cancer32(1), 1–8 (1973).
   PubMed Web of Science ®Google Scholar
• Tan C, Etcubanas E, Wollner N et al. Adriamycin – an antitumor antibiotic in the treatment of neoplastic diseases. Cancer32(1), 9–17 (1973).
   PubMed Web of Science ®Google Scholar
• Bergeron C, Thiesse P, Rey A et al. Revisiting the role of doxorubicin in the treatment of rhabdomyosarcoma: an up-front window study in newly diagnosed children with high-risk metastatic disease. Eur. J. Cancer44(3), 427–431 (2008).
   PubMedGoogle Scholar
• Pratt CB, Crom DB. Cisplatin and doxorubicin for locally recurrent and metastatic childhood rhabdomyosarcoma. Chemioterapia3(4), 207–210 (1984).
   PubMedGoogle Scholar
• Etcubanas E, Horowitz M, Vogel R. Combination of dacarbazine and doxorubicin in the treatment of childhood rhabdomyosarcoma. Cancer Treat. Rep.69(9), 999–1000 (1985).
   PubMedGoogle Scholar
• Womer RB. The Intergroup Rhabdomyosarcoma Studies come of age. Cancer71(5), 1719–1721 (1993).
   PubMedGoogle Scholar
• Arndt CA, Hawkins DS, Meyer WH, Sencer SF, Neglia JP, Anderson JR. Comparison of results of a pilot study of alternating vincristine/doxorubicin/cyclophosphamide and etoposide/ifosfamide with IRS-IV in intermediate risk rhabdomyosarcoma: a report from the Children’s Oncology Group. Pediatr. Blood Cancer50(1), 33-36 (2006).
   Google Scholar
• Smith MA, Ungerleider RS, Horowitz ME, Simon R. Influence of doxorubicin dose intensity on response and outcome for patients with osteogenic sarcoma and Ewing’s sarcoma. J. Natl Cancer Inst.83(20), 1460–1470 (1991).
   PubMed Web of Science ®Google Scholar
• Bisogno G, Ferrari A, Bergeron C et al. The IVADo regimen – a pilot study with ifosfamide, vincristine, actinomycin D, and doxorubicin in children with metastatic soft tissue sarcoma: a pilot study on behalf of the European pediatric Soft tissue sarcoma Study Group. Cancer103(8), 1719–1724 (2005).
   PubMed Web of Science ®Google Scholar
• Ferrari A, Casanova M, Bisogno G et al. Rhabdomyosarcoma in infants younger than one year old: a report from the Italian Cooperative Group. Cancer97(10), 2597–2604 (2003).
   PubMedGoogle Scholar
• Stiller CA, Stevens MC, Magnani C, Corazziari I. Survival of children with soft-tissue sarcoma in Europe since 1978: results from the EUROCARE study. Eur. J. Cancer37(6), 767–774 (2001).
   PubMedGoogle Scholar
• La Quaglia MP, Heller G, Ghavimi F et al. The effect of age at diagnosis on outcome in rhabdomyosarcoma. Cancer73(1), 109–117 (1994).
   PubMed Web of Science ®Google Scholar
• Arndt C, Hawkins D, Anderson JR, Breitfeld P, Womer R, Meyer W. Age is a risk factor for chemotherapy-induced hepatopathy with vincristine, dactinomycin, and cyclophosphamide. J. Clin. Oncol.22(10), 1894–1901 (2004).
   PubMed Web of Science ®Google Scholar
• Carli M, Colombatti R, Oberlin O et al. European intergroup studies (MMT4–89 and MMT4–91) on childhood metastatic rhabdomyosarcoma: final results and analysis of prognostic factors. J. Clin. Oncol.22(23), 4787–4794 (2004).
   PubMed Web of Science ®Google Scholar
• Koscielniak E, Rodary C, Flamant F et al. Metastatic rhabdomyosarcoma and histologically similar tumors in childhood: a retrospective European multi-center analysis. Med. Pediatr. Oncol.20(3), 209–214 (1992).
   PubMedGoogle Scholar
• Oberlin O, Rey A, Lyden E et al. Prognostic factors in metastatic rhabdomyosarcomas: results of a pooled analysis from United States and European cooperative groups. J. Clin. Oncol.26(14), 2384–2389 (2008).
   PubMed Web of Science ®Google Scholar
• Koscielniak E, Klingebiel TH, Peters C et al. Do patients with metastatic and recurrent rhabdomyosarcoma benefit from high-dose therapy with hematopoietic rescue? Report of the German/Austrian Pediatric Bone Marrow Transplantation Group. Bone Marrow Transplant.19(3), 227–231 (1997).
   PubMed Web of Science ®Google Scholar
• Carli M, Colombatti R, Oberlin O et al. High-dose melphalan with autologous stem-cell rescue in metastatic rhabdomyosarcoma. J. Clin. Oncol.17(9), 2796–2803 (1999).
   PubMed Web of Science ®Google Scholar
• Weigel BJ, Breitfeld PP, Hawkins D, Crist WM, Baker KS. Role of high-dose chemotherapy with hematopoietic stem cell rescue in the treatment of metastatic or recurrent rhabdomyosarcoma. J. Pediatr. Hematol. Oncol.23(5), 272–276 (2001).
   PubMed Web of Science ®Google Scholar
• Raney RB Jr, Tefft M, Maurer HM et al. Disease patterns and survival rate in children with metastatic soft-tissue sarcoma. A report from the Intergroup Rhabdomyosarcoma Study (IRS)-I. Cancer62(7), 1257–1266 (1988).
   PubMed Web of Science ®Google Scholar
• Bisogno G, Ferrari A, Prete A et al. Sequential high-dose chemotherapy for children with metastatic rhabdomyosarcoma. Eur. J. Cancer45(17), 3035–3041 (2009).
   PubMedGoogle Scholar
• Mackall CL, Helman LJ. High-dose chemotherapy for rhabdomyosarcoma: where do we go from here. J. Pediatr. Hematol. Oncol.23(5), 266–267 (2001).
   PubMed Web of Science ®Google Scholar
• Meyers PA. High-dose therapy with autologous stem cell rescue for pediatric sarcomas. Curr. Opin. Oncol.16(2), 120–125 (2004).
   PubMed Web of Science ®Google Scholar
• Donker AE, Hoogerbrugge PM, Mavinkurve-Groothuis AM et al. Metastatic rhabdomyosarcoma cured after chemotherapy and allogeneic SCT. Bone Marrow Transplant.43(2), 179–180 (2009).
   PubMedGoogle Scholar
• Womer RB, Daller RT, Fenton JG, Miser JS. Granulocyte colony stimulating factor permits dose intensification by interval compression in the treatment of Ewing’s sarcomas and soft tissue sarcomas in children. Eur. J. Cancer36(1), 87–94 (2000).
   PubMed Web of Science ®Google Scholar
• Weigel B, Lyden E, Anderson JR et al. Early results from Children’s Oncology Group (COG) ARST0431: intensive multidrug therapy for patients with metastatic rhabdomyosarcoma (RMS). J. Clin. Oncol.28(7 Suppl.) (2010) (Abstract 9503).
   PubMedGoogle Scholar
• Pui CH, Evans WE. Treatment of acute lymphoblastic leukemia. N. Engl. J. Med.354(2), 166–178 (2006).
   PubMed Web of Science ®Google Scholar
• Hanahan D, Bergers G, Bergsland E. Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J. Clin. Invest.105(8), 1045–1047 (2000).
   PubMed Web of Science ®Google Scholar
• Kerbel RS, Klement G, Pritchard KI, Kamen B. Continuous low-dose anti-angiogenic/metronomic chemotherapy: from the research laboratory into the oncology clinic. Ann. Oncol.13(1), 12–15 (2002).
   PubMed Web of Science ®Google Scholar
• Casanova M, Ferrari A, Bisogno G et al. Vinorelbine and low-dose cyclophosphamide in the treatment of pediatric sarcomas: pilot study for the upcoming European Rhabdomyosarcoma Protocol. Cancer101(7), 1664–1671 (2004).
   PubMed Web of Science ®Google Scholar
• Kuttesch JF Jr, Krailo MD, Madden T, Johansen M, Bleyer A. Phase II evaluation of intravenous vinorelbine (Navelbine) in recurrent or refractory pediatric malignancies: a Children’s Oncology Group study. Pediatr. Blood Cancer53(4), 590–593 (2009).
   PubMed Web of Science ®Google Scholar
• Casanova M, Ferrari A, Spreafico F et al. Vinorelbine in previously treated advanced childhood sarcomas: evidence of activity in rhabdomyosarcoma. Cancer94(12), 3263–3268 (2002).
   PubMed Web of Science ®Google Scholar
• Klement G, Baruchel S, Rak J et al. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J. Clin. Invest.105(8), R15–R24 (2000).
   PubMed Web of Science ®Google Scholar
• Hill SA, Lonergan SJ, Denekamp J, Chaplin DJ. Vinca alkaloids: anti-vascular effects in a murine tumour. Eur. J. Cancer29A(9), 1320–1324 (1993).
   PubMed Web of Science ®Google Scholar
• Hill SA, Lonergan SJ, Denekamp J, Chaplin DJ. The effect of vinca alkaloids on tumour blood flow. Adv. Exp. Med. Biol.345, 417–422 (1994).
   PubMedGoogle Scholar
• Hill SA, Sampson LE, Chaplin DJ.Anti-vascular approaches to solid tumour therapy: evaluation of vinblastine and flavone acetic acid. Int. J. Cancer63(1), 119–123 (1995).
   PubMed Web of Science ®Google Scholar
• Ma J, Waxman DJ. Modulation of the antitumor activity of metronomic cyclophosphamide by the angiogenesis inhibitor axitinib. Mol. Cancer Ther.7(1), 79–89 (2008).
   PubMed Web of Science ®Google Scholar
• Linden O, Greiff L, Wahlberg P, Vinge E, Kjellen E. Chemorefractory rhabdomyosarcoma treated with radiotherapy, bevacizumab, statins and surgery and maintenance with bevacizumab and chemotherapy. Onkologie31(7), 391–393 (2008).
   PubMedGoogle Scholar
• Benesch M, Windelberg M, Sauseng W et al. Compassionate use of bevacizumab (Avastin) in children and young adults with refractory or recurrent solid tumors. Ann. Oncol.19(4), 807–813 (2008).
   PubMed Web of Science ®Google Scholar
• Wan X, Helman LJ. The biology behind mTOR inhibition in sarcoma. Oncologist12(8), 1007–1018 (2007).
   PubMed Web of Science ®Google Scholar
• Houghton PJ, Morton CL, Kolb EA et al. Initial testing (stage 1) of the mTOR inhibitor rapamycin by the pediatric preclinical testing program. Pediatr. Blood Cancer50(4), 799–805 (2008).
   PubMed Web of Science ®Google Scholar
• Mita MM, Mita AC, Chu QS et al. Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies. J. Clin. Oncol.26(3), 361–367 (2008).
   PubMed Web of Science ®Google Scholar
• Buckner JC, Forouzesh B, Erlichman C et al. Phase I, pharmacokinetic study of temsirolimus administered orally to patients with advanced cancer. Invest. New Drugs28(3), 334–342 (2009).
   PubMedGoogle Scholar
• Dancey JE, Curiel R, Purvis J. Evaluating temsirolimus activity in multiple tumors: a review of clinical trials. Semin. Oncol.36(Suppl. 3), S46–S58 (2009).
   PubMedGoogle Scholar
• Stock C, Zaccagnini M, Schulze M, Teber D, Rassweiler JJ. Temsirolimus. Recent ResultsCancer Res.184, 189–197 (2010).
   PubMedGoogle Scholar
• LeRoith D, Roberts CT Jr. The insulin-like growth factor system and cancer. Cancer Lett.195(2), 127–137 (2003).
   PubMed Web of Science ®Google Scholar
• Kolb EA, Gorlick R, Houghton PJ et al. Initial testing (stage 1) of a monoclonal antibody (SCH 717454) against the IGF-1 receptor by the pediatric preclinical testing program. Pediatr. Blood Cancer50(6), 1190–1197 (2008).
   PubMed Web of Science ®Google Scholar
• Malempati S, Weigel B, Ingle AM et al. A Phase I trial and pharmacokinetic study of IMC-A12 in pediatric patients with relapsed/refractory solid tumors: a Children’s Oncology Group Phase I Consortium study. J. Clin. Oncol.27(15 Suppl.) (2009) (Abstract 10013).
   Google Scholar
• Driman D, Thorner PS, Greenberg ML, Chilton-MacNeill S, Squire J. MYCN gene amplification in rhabdomyosarcoma. Cancer73(8), 2231–2237 (1994).
   PubMed Web of Science ®Google Scholar
• Forus A, Florenes VA, Maelandsmo GM, Meltzer PS, Fodstad O, Myklebost O. Mapping of amplification units in the q13–14 region of chromosome 12 in human sarcomas: some amplica do not include MDM2. Cell Growth Differ.4(12), 1065–1070 (1993).
   PubMedGoogle Scholar
• Ablett S, Doz F, Morland B, Vassal G. European collaboration in trials of new agents for children with cancer. Eur. J. Cancer40(12), 1886–1892 (2004).
   PubMed Web of Science ®Google Scholar
• Houghton PJ, Adamson PC, Blaney S et al. Testing of new agents in childhood cancer preclinical models: meeting summary. Clin. Cancer Res.8(12), 3646–3657 (2002).
   PubMed Web of Science ®Google Scholar
• Gallego S, Llort A, Roma J, Sabado C, Gros L, de Toledo JS. Detection of bone marrow micrometastasis and microcirculating disease in rhabdomyosarcoma by a real-time RT-PCR assay. J. Cancer Res. Clin. Oncol.132(6), 356–362 (2006).
   PubMedGoogle Scholar
• Sartori F, Alaggio R, Zanazzo G et al. Results of a prospective minimal disseminated disease study in human rhabdomyosarcoma using three different molecular markers. Cancer106(8), 1766–1775 (2006).
   PubMedGoogle Scholar